All Industries

Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Could Upend The $15 Billion Market

Medicus Pharma Ltd (MDCX)

Skin cancer is the most common form of cancer in the United States, with more than 9,500 cases getting diagnosed every day. In fact, more people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. The most common form of skin cancer is basal cell carcinoma (BCC), which accounts for over 5 million cases of all skin cancers diagnosed in the U.S. each year. Currently, the standard treatment for most BCC patients is surgery, either standard excision or Mohs micrographic surgery, which has led to a significant unmet medical need for a non-surgical option. That is why Medicus Pharma Ltd. (NASDAQ:MDCX), a life sciences company focused on accelerating the clinical development programs of novel therapeutic assets, has been attracting investor attention with its revolutionary new treatment that is under development. A non-invasive novel approach Medicus, through its wholly owned subsidiary SkinJect Inc., is focused on commercializing a novel, non-invasive treatment for basal cell carcinoma using a patented dissolvable microneedle patch. The patch is thumb-sized, and what makes it particularly unique is its ability to deliver a chemotherapeutic agent (doxorubicin) to kill tumor cells on the skin and induce a memory immune response to prevent cancer recurrence. Microneedles are promising devices for painless drug delivery, which can improve the biological effect of drugs through adjustable drug release. This novel non-invasive regimen to treat skin cancer, especially BCC, therefore represents a potentially attractive alternative to surgery and current topical therapeutic options. So far, preliminary trial results have been quite promising. The company completed a Phase I study for SkinJect in March 2021 for participants with superficial and nodular BCC, which met its primary objective of safety and tolerability. In January 2024, a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study that began enrollment in August with 60 patients. According to Medicus, an interim analysis of the ongoing clinical study reveals that SKNJCT-003 is trending positively, with a proportion of subjects with complete clinical clearance of more than 60%. In April this year, the company announced that the Institutional Review Board (IRB) had approved an increase in the number of patients from 60 to 90, further highlighting the company’s progress towards validation. The company plans to submit the interim analysis to the FDA as part of a package seeking a Type C meeting with the regulator in Q2 2025 with the aim of seeking approval to fast-track the clinical development program. At the same time, the company has said that it will be expanding the phase 2 clinical study into additional sites in the US from the current nine sites as well as two clinical trial sites in Europe. In addition to that, Medicus has received the study may proceed approval from the UAE Department of Health to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC. The study is expected to randomize 36 patients in four sites in the UAE. It’s also important to note that the company hasn't limited SkinJect to treating humans only. Last year Medicus received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. MUMS is a designation that is comparable to orphan drug status for human medications. Earlier this month, the company revealed that it had submitted a comprehensive product development plan to treat external SCC under Investigational New Animal Drug, designed to seek concurrence of the FDA under MUMS designation. Significant revenue opportunity As mentioned earlier, the potential addressable market for SkinJect is quite significant. About 40–50% of Americans who live to age 65 will experience BCC or SCC at least once. And while still most prevalent in the older segments of the population, it is becoming ever more frequent in younger individuals. BCC procedures are projected to grow at 4% per annum, reaching 6 million procedures in 2030, representing a market size in excess of $15 billion annually, and Medicus is well positioned to capture a significant share of this market if SkinJect is approved due to a couple of reasons. For starters, it is a less painful, less invasive way to treat skin cancer and also lowers the likelihood of recurrence. Secondly, while Mohs surgery costs range between $2,000 and $15,000, the cost of three SkinJect microneedle patches is estimated at $1,000, illustrating the potential for significant cost savings for patients. Furthermore, SkinJect can be administered the same day as a diagnosis, while the average lead time for surgery in the US spans 2–8 months. Apart from that, the overall incidence of SCC in horses is 2-3%, and recent estimates of the US horse population range from 6.6 to 7.25 million horses. With only a handful of approved oncology drugs in the veterinary market, the company believes that developing a non-invasive treatment for equine SCC represents an untapped and unmet market opportunity potentially in the range of $250 million. Medicus has continued to show its commitment to unlocking more shareholder value with its recent announcement of a binding letter of intent to acquire Antev Ltd. for $75 million in a share exchange transaction. Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. Collectively, this represents an additional $6 billion in potential market opportunities for Medicus. Antev shareholders will receive an aggregate 19% equity stake in Medicus, plus $65 million in additional contingent payments tied to potential future FDA Phase 2 and New Drug Application approvals. The transaction is expected to close before the end of June. Takeaway Medicus recently announced the closing of its $7 million public offering, which will be used to fund its Phase 2 proof-of-concept clinical trial, further illustrating investor confidence in the company’s progress so far and future prospects. As such, investors searching for a unique opportunity in the cancer treatment space should consider taking a closer look at Medicus before it gains mainstream traction. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 24, 2025 07:00 AM Eastern Daylight Time

Clarion Partners Makes First Investment in Bozeman, Montana Market

Clarion Partners

Clarion Partners, LLC, a leading real estate investment manager, is partnering with Wentworth Property Company to develop Highmark, a new 162-unit townhome and apartment community in Bozeman, MT. Located in a Qualified Opportunity Zone (QOZ) on 8+ acres in the broader South University District master-planned neighborhood, Highmark is bringing high-quality rental housing options to one of the most rapidly growing micropolitan areas in the U.S. Leasing began in April 2025, and the project is scheduled for completion in late 2025. Inclusive of a broad range of unit styles, from single bedroom apartments to 3-story townhomes, the community, situated less than a half mile from the Montana State University campus and less than two miles from Downtown Bozeman, offers a variety of living accommodations for families and students alike. “Bozeman offers an unparalleled outdoor lifestyle as well as proximity to a growing education and technology employment base,” said Clarion Partners Managing Director Jason Glasser. “The development of Highmark will add a variety of new housing options in a popular area where home prices have become increasingly unaffordable.” Units feature 10-ft ceilings, modern kitchens with quartz countertops and stainless steel appliances, wood-vinyl flooring, ample storage, full size washing machines and dryers, and individual yards and balconies for the townhomes. Community amenities include a clubroom, fitness center, package locker room, outdoor gathering area, hot tub, dog park, pet spa, and over 300 parking spaces. Clarion is currently invested in 170 properties (nearly $8 billion in GRE) in areas designated as QOZs and owns an additional 734 properties (over $38 billion in GRE) in submarkets neighboring U.S. QOZs. 1 About Clarion Partners Clarion Partners, an SEC registered investment adviser with FCA-authorized and FINRA member affiliates, has been a leading U.S. real estate investment manager for more than 40 years. Headquartered in New York, the firm maintains strategically located offices across the United States and Europe. With over $73 billion in total real estate and debt assets under management, Clarion Partners offers a broad range of real estate strategies across the risk/return spectrum to 500 institutional investors across the globe. For more information visit www.clarionpartners.com. 1 As of December 31, 2024 Contact Details Chris Sullivan +1 917-902-0617 chris@craftandcapital.com Company Website https://www.clarionpartners.com

June 23, 2025 04:00 PM Eastern Daylight Time

Image

Lehman Pipe Announces Strategic Acquisition of Cole Industrial

Rotunda Capital Partners LLC

Lehman Pipe and Supply, LLC, a portfolio company of Rotunda Capital Partners, is proud to announce the acquisition of Cole Industrial, a highly respected name in industrial distribution across Florida and beyond. This strategic partnership brings together two industry leaders with shared values, complementary strengths, and a common vision for long-term growth centered on delivering exceptional value to the customers and communities they serve. While the transaction represents a formal acquisition, both organizations view this as a true partnership rooted in mutual respect and a commitment to the trades. For more than 25 years, Cole Industrial has earned a reputation for technical expertise, strong customer relationships, and operational excellence; principles that align closely with Lehman Pipe’s long-standing mission. By combining Cole’s industrial expertise with Lehman’s deep commercial foundation, the unified company will offer customers an expanded product offering, enhanced inventory availability, and more tailored solutions across vertical markets including industrial, commercial, plumbing, mechanical, and fire protection. This integration allows both teams to better serve evolving market needs while helping customers reduce total project costs and increase efficiency. Cole Industrial will continue operating under its name as the industrial division of Lehman Pipe, retaining the trusted team customers know, now supported by broader resources and expanded capabilities. Over time, both organizations will adopt shared technologies, tools, and best practices to further improve service delivery and operational efficiency without compromising the high standards and relationships that have defined their success. "Joining forces with Lehman Pipe and Rotunda Capital Partners is an exciting new chapter for Cole Industrial. What stood out to me from the beginning was how closely our values align, a deep respect for the trades, a relentless focus on customer service, and a commitment to doing things the right way. The combined talent across both teams is exceptional, and there’s a shared energy and ambition that’s truly contagious. While this is a significant transition, I couldn’t be more confident in the direction we’re heading together and am genuinely excited for what’s ahead." said Michael Torres, Former Owner, Cole Industrial. “We are excited to welcome the Cole team to Lehman Pipe,” said Josh Aberman, CEO of Lehman Pipe. “They’ve built something truly special, and we’re honored to continue that legacy while creating new opportunities for growth, together!” Josh further expanded, “To existing customers of both Cole and Lehman, the message is clear: your trust made this possible, and this partnership is designed with your success in mind. To prospective customers, the company looks forward to earning your business by delivering unmatched service, reliability, and value.” About Lehman Pipe and Supply, LLC Lehman Pipe and Supply, LLC is a leading wholesale distributor of pipe, valves, and fittings, serving a broad range of vertical markets including commercial construction, industrial manufacturing, mechanical systems, plumbing infrastructure, and fire protection. Founded in 1946, Lehman has built a strong reputation for service reliability, deep inventory, and logistical expertise. The company is focused on scaling its platform through operational excellence, data-driven decision-making, and strategic partnerships to deliver tailored solutions that help customers reduce project costs and improve efficiency. For more information, visit www.lehmanpipe.com. About Rotunda Capital Partners Rotunda Capital Partners is an operationally oriented private equity firm focused on transforming family-founder owned companies into dynamic, data-driven platforms able to achieve and manage significant growth. Since its founding in 2009, Rotunda has partnered with management teams to build great businesses within three primary sectors: value-added distribution, asset-light logistics and industrial, business & residential services. Rotunda strives to achieve replicable results by implementing its Rotunda Performance System to create strategic alignment, develop lean processes and create robust, data-driven infrastructures. For more information, visit www.rotundacapital.com. Contact Details Rotunda Capital Partners Margaux Valle +1 240-962-1707 PR@rotundacapital.com Company Website https://www.rotundacapital.com

June 23, 2025 12:50 PM Eastern Daylight Time

News Release

The $4.1 Trillion Healthcare Revolution: How DarioHealth Could Rewrite the Rules of Chronic Disease Management

Global Markets News

Imagine a world where managing multiple chronic conditions isn’t a nightmare of fragmented care, endless appointments, and mounting medical bills. This isn’t a futuristic fantasy, it’s the vision of DarioHealth Corp. (NASDAQ: DRIO)*, a digital health company that’s quietly building what could be the most comprehensive solution to America’s chronic disease crisis. The numbers are staggering. Chronic diseases consume a mind-boggling 90% of the $4.1 trillion U.S. healthcare budget, according to the CDC. Worse, 42% of Americans juggle multiple chronic conditions, with 12% managing five or more. It’s a system broken beyond repair, or so it seemed. Enter DarioHealth, a digital health innovator that’s reimagining healthcare from the ground up. Unlike traditional point solutions that tackle one condition at a time, this company has developed an AI-powered platform that simultaneously addresses diabetes, hypertension, weight management, musculoskeletal pain, and mental health. The company’s journey is as compelling as its technology. Born from years of user interaction data spanning 150,000 consumers, DarioHealth has built more than just an app, it’s created an intelligent ecosystem that learns and adapts to individual health journeys. Their AI-driven platform isn’t just tracking metrics; it’s predicting and preventing health complications before they escalate. But this isn’t just another tech pipe dream. The company’s approach is delivering real-world results that are turning heads across the healthcare industry. Imagine reducing hyperglycemic events by 58%, cutting anxiety symptoms by 59%, and delivering a 5x return on investment for healthcare payers. These aren’t marketing promises, they’re proven outcomes. The GLP-1 weight loss revolution provides a perfect window into DarioHealth’s strategic brilliance. With the weight loss medication market set to explode to $100 billion by 2030, the company has positioned itself as more than just a support platform. Through a strategic partnership with MediOrbis, they now offer integrated medication prescribing, solving the critical problem that sees 75% of patients discontinuing GLP-1 medications within a year. 2025 has been a breakthrough year. The company has added 14 new clients, bringing their total to 97 organizations. More importantly, over 80% of new contracts now cover multiple health conditions, a clear validation of their holistic approach. Major players like Blue Cross Blue Shield are taking notice, and the company’s client renewal rate sits at an impressive 90%. Financially, the story is equally compelling. First-quarter 2025 revenues hit $6.75 million, a 17% year-over-year growth. But the real magic is happening behind the scenes. The company is deploying AI to streamline operations, with a laser focus on reaching operational cash flow breakeven by the end of 2025 or early 2026. Recent industry comparisons, like the recent IPO of Omada Health (NASDAQ: OMDA) at much higher multiples, highlight the potential undervaluation of DarioHealth’s innovative platform. For investors tired of overhyped tech promises, DarioHealth may offer something different. Trading at around $0.69 with a market cap of ~$30 million, this could be the definition of a hidden gem. The company isn’t just building a product, it’s reimagining how chronic disease management could work in the digital age. Consider the market opportunity. With 129 million Americans suffering from at least one major chronic disease, and healthcare costs continuing to spiral, DarioHealth sits at the intersection of a massive market need and technological innovation. Recent analyst reports have even suggested the stock could reach $3, a potential 335% upside from current levels. This isn’t just another digital health play. This is a potential blueprint for the future of healthcare, personalized, integrated, and powered by intelligent technology. In a world where healthcare complexity continues to grow, DarioHealth represents a beacon of hope, promising not just management, but meaningful transformation of how we approach chronic health. ‎ ‎ Recent News Highlights from Dario DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025 DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives - * Legal Disclaimer & Disclosure - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from DarioHealth Corp. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. Contact Details ‎ media.globalmarkets@gmail.com

June 23, 2025 10:54 AM Eastern Daylight Time

G6 Hospitality’s Revenue Management Program Delivers Double-Digit Growth and Outperforms Market

G6 Hospitality LLC

G6 Hospitality, parent company of Motel 6 and Studio 6, today announced the results of its Revenue Management Services (RMS) program, which continues to deliver superior performance for participating properties compared to the broader portfolio and the market at large. The RMS program leverages proprietary automation tools, daily competitive set monitoring, and bi-weekly strategy calls with dedicated revenue managers. These initiatives allow general managers to focus on guest experience while G6’s experts optimize pricing, channel mix, and promotional strategies. Properties enrolled in the G6 Revenue Management Services program saw an impressive 11% year-over-year revenue growth in the first quarter of 2025, more than double the growth rate of the rest of the portfolio and significantly ahead of industry benchmarks. These properties also achieved a 10% higher Average Daily Rate (ADR) compared to non-RMS properties, reflecting the program’s effectiveness in optimizing pricing and maximizing revenue opportunities. The RMS program’s impact is especially pronounced on G6’s app & website. In Q1 2025, properties under revenue management saw web and app channel growth of 11.5%, while the rest of the portfolio experienced a 4.4% decline. This digital uplift is driven by advanced dynamic pricing, OTA optimization, and a dedicated central performance marketing team that ensures each property is positioned to capture demand across all segments. The program continued to demonstrate momentum in April 2025. Revenue-managed properties posted a 9% revenue growth for the month, compared to just 0.7% for non-revenue managed hotels. Web channel growth for RMS properties stood at 11%, dramatically outpacing the 0.6% growth for non-RMS properties. Average Daily Rate (ADR) for RMS properties reached $78.24, a significant premium over the $66.68 ADR for non-managed properties. “Our Revenue Management Services program is designed to empower our franchisees with cutting-edge tools, strategic expertise, and real-time data to drive results,” said Sonal Sinha, CEO of G6 Hospitality. “The success we’re seeing—higher ADR, more direct bookings, and significant revenue growth—demonstrates the value of our hands-on, data-driven approach. We’re proud to help our partners outperform the market and deliver exceptional value to their guests.” This announcement follows G6 Hospitality’s recent launch of the AI-powered My6 app, which delivers a faster, more personalized booking experience and has already driven a 14% year-over-year increase in direct bookings. Together, these initiatives underscore G6 Hospitality’s commitment to leveraging technology and data to drive growth, enhance guest satisfaction, and support franchisee success. About G6 Hospitality LLC G6 Hospitality LLC is the leading economy lodging franchisor, with nearly 1,500 economy lodging locations under the iconic Motel 6 and Studio 6 brands in the United States and Canada. G6 Hospitality is committed to making hospitality accessible to all through responsible business practices and unparalleled opportunity for franchisees to build a legacy through ownership. Both Motel 6 and Studio 6 were recognized in the 2024 Entrepreneur Franchise 500® report, with Motel 6 ranking in the top 50 of all franchises. The Carrollton, Texas-based company was named a 2024 Leader in Diversity by Dallas Business Journal. For more information, please visit www.g6hospitality.com. Contact Details G6 Hospitality LLC Anupriya +91 97911 63065 anupriya.d@g6hospitality.com Company Website https://g6hospitality.com/

June 23, 2025 10:00 AM Eastern Daylight Time

California's Donor Milk Law Creates Need for More Milk Donors as Demand Surges 30%

The Mothers' Milk Bank

Six months after California's groundbreaking Assembly Bill 3059 expanded insurance coverage and hospital access to life-saving donor milk, Mothers’ Milk Bank California is facing a 30% surge in demand, leaving vulnerable newborns at risk of going without this essential nutrition. Mothers’ Milk Bank California is urging eligible nursing mothers to donate and help meet the growing needs of medically fragile newborns across the state. AB3059, also known as the Human Milk Bill, mandates commercial insurance coverage for medically necessary pasteurized donor human milk, treating it as an essential health benefit. It also clarifies that hospitals do not need a tissue bank license to distribute milk from a licensed tissue bank, eliminating a key barrier to access. While this legislation represents a tremendous victory for vulnerable infants and their families by making life-saving donor milk more accessible and affordable, it has created an unprecedented surge in demand that is straining the current supply. The expanded insurance coverage means more families can now access donor milk for their medically fragile babies, but the donor base has not kept pace with the new surge in demand for human milk. Without additional donors, wait times for families may increase, and some infants who desperately need donor milk may face delays in receiving this vital nutrition. The success of AB3059 depends not only on policy change but on community action. Eligible mothers can help bridge this supply gap to try to ensure every baby who needs donor milk can receive it without delay. “This is a breakthrough in equitable neonatal care,” said Jennifer Benito, CEO of Mothers’ Milk Bank California. “But we need the public’s help to meet the rising demand to try to ensure that every baby receives this lifesaving nourishment.” In 2023, California recorded over 36,000 preterm births, and many of these fragile infants relied on donor milk to thrive. Now, use of donor milk is increasing not only in NICUs but also in Well Baby and Postpartum units, where emerging research shows it may reduce feeding complications, support gut health, and lower the risk of hospital readmissions, even for full-term newborns. “We’ve normalized blood donation as a vital act of generosity. It’s time we do the same for breast milk,” said Benito. “Because of AB3059, Mothers’ Milk Bank California is seeing a dramatic 30% increase in demand for donor milk—a spike we believe is directly tied to expanded insurance coverage and the removal of the tissue bank license requirement for hospitals. Every ounce donated can mean the difference between stability and struggle for a newborn.” New Ways to Donate: Easier Than Ever To meet this moment, Mothers’ Milk Bank California is expanding access and support for donors with multiple convenient options: Saturday Donor Screening Appointments Now Available To better support busy families, Mothers’ Milk Bank California now offers virtual donor screenings on Saturdays from 9:00 AM to 1:00 PM. Prospective donors can schedule an appointment by visiting our website or calling 1-877-375-6645 (option 3). At-Home Milk Pick-Up: June 23 – August 15, 2025 Donating milk is now as simple as opening your front door. From Monday to Friday, 8:00 AM to 6:00 PM, eligible donors in San Mateo, Santa Clara, and Alameda Counties can schedule doorstep milk pick-up. Need help with packing? We’ve got you covered—just mention it when confirming your pickup. Drop-Off at Our San Jose Headquarters or Collection Centers Mothers’ Milk Bank California–approved donors can schedule an appointment to deliver milk directly to our headquarters in San Jose, California. To schedule a convenient time, give the Mothers’ Milk Bank California a call at 1-877-375-6645 (option 3). Approved donors may also drop off milk at one of our designated collection centers located throughout the state. Please note: To ensure we’re ready to receive your donation, all drop-offs are by appointment only and available to donors who have completed our screening process. For media inquiries or to schedule an interview with a member of the Mothers’ Milk Bank California team, please call or email Cheryl@Landispr.com or (415) 640-5431. To access B-roll footage of our processing facility, donor stories, or hospital partnerships, please visit our newsroom. Founded 50 years ago, Mothers' Milk Bank California is a leading nonprofit dedicated to providing screened, donated human milk to babies in need. As a founding member of the Human Milk Banking Association of North America (HMBANA), it helped set standards for nonprofit milk banks across North America. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families, ensuring essential nutrition for infants. Committed to improving lives, Mother's Milk Bank California supports families and advances neonatal care. Contact Details Jennifer Benito-Kowalski +1 408-831-7276 jbenito@mothersmilk.org Company Website https://mothersmilk.org/

June 23, 2025 06:03 AM Pacific Daylight Time

News Release

Public Companies Are Turning to Crypto: 4 Stocks Leading the Treasury Revolution

DBKSF MSTR SBET DFDV

A new financial playbook is emerging among public companies in 2025: replace traditional cash reserves with crypto assets. Once considered fringe, crypto treasury strategies—allocating corporate capital to digital currencies—are rapidly going mainstream. The shift began with MicroStrategy’s bold Bitcoin purchases in 2020, but this year, the trend has accelerated across multiple blockchains. From large caps to speculative tech players, companies are turning to Bitcoin, Ethereum, Solana, and newer entrants like Sonic coin to protect against inflation, earn yield, and attract a new generation of investors. What was once an eccentric bet has now evolved into a diversified movement. Public companies are not just buying crypto—they’re staking it, building validator infrastructure, and generating passive yield. For investors, these businesses offer exchange-listed exposure to digital assets, often with strategic advantages like regulatory clarity, leverage, or ecosystem access. Below are four companies at the forefront of this movement. 1. Strategy (NASDAQ: MSTR)—The Bitcoin Benchmark Formerly known as MicroStrategy, Strategy is the original corporate crypto bull. As of June 2025, the company holds 580,955 BTC, valued at approximately $61.4 billion USD, making it the largest public holder of Bitcoin by far. Its strategy is unapologetically aggressive: borrow capital through convertible notes and share offerings, then deploy that cash into Bitcoin. Strategy treats BTC as a superior treasury reserve asset, betting on its long-term appreciation over fiat. CEO Michael Saylor has framed the move as both a hedge against inflation and a bold capital allocation thesis. This leveraged Bitcoin position has fundamentally changed the company’s identity. No longer judged on software revenues, Strategy now trades as a quasi–Bitcoin ETF with embedded operational leverage. Its stock has soared nearly 3,000% since initiating the pivot, becoming a proxy for institutional BTC exposure and a playbook many are beginning to replicate. 2. Spetz Inc. (CSE: SPTZ | OTC: DBKSF)—The Sonic Coin Specialist Spetz Inc. is at the vanguard of next-generation altcoin treasury strategies, centered on Sonic coin ($S)—the native token of the Sonic blockchain, a high-speed, low-cost Layer 1 network gaining traction in developer activity and decentralized finance. As of June 2025, Spetz holds 6 million $S tokens purchased at an average of $0.39 USD, giving it a crypto treasury valued at over $3.3 million CAD. Instead of simply holding tokens, the company operates a Sonic validator node —earning an estimated 4.62% APY in staking rewards while directly supporting the chain’s security and governance. This validator model turns idle capital into a productive asset, creating a recurring yield stream and positioning Spetz as a core infrastructure player in a fast-scaling blockchain ecosystem. The company is also exploring additional yield strategies, including smart contract–enabled staking pools and integrations with Sonic-native DeFi protocols—marking a shift from passive tokenholder to active crypto-native allocator. In May, Spetz completed a $10 million CAD private placement to accelerate this strategy. The funds will support validator expansion, token accumulation, and deeper integration with the Sonic ecosystem. The company is also evaluating cross-chain staking and yield aggregation across upcoming Sonic Layer 2 networks, reinforcing its long-term vision as an infrastructure-driven treasury operator. For investors, Spetz offers early-stage, high-conviction exposure to one of 2025’s most closely watched altcoin ecosystems. It provides not just financial exposure but operational leverage: token upside, staking rewards, and protocol-level participation—all without the friction or custodial risk of managing crypto assets directly. 3. SharpLink Gaming (NASDAQ: SBET)—Ethereum’s Corporate Powerhouse SharpLink Gaming made headlines—and waves—when it pivoted from gaming tech to Ethereum treasury accumulation. In Q2 2025, it raised $425 million USD via PIPE financing and deployed it into 176,271 ETH, making it the largest public Ethereum holder globally. More than 95% of its ETH is staked, earning rewards via both native and liquid staking protocols. This approach is less about trading and more about long-term ETH accumulation with a recurring income stream, backed by validator rewards and DeFi integrations. Initially, markets were caught off guard—the stock dropped over 90% post-pivot—but SharpLink has since clarified its roadmap. With ties to Joseph Lubin and Consensys, the company is carving out a unique niche as a Web3-native treasury allocator, betting that Ethereum’s Layer 2 scaling, restaking protocols, and yield dynamics will compound value over time. 4. DeFi Development Corp. (NASDAQ: DFDV)—Solana’s Institutional Backer DeFi Development Corp., formerly Janover Inc., is executing one of the boldest Solana-centric treasury strategies in the public markets. With a treasury of 609,190 SOL and a recent purchase of 16,447 SOL at $139.66 USD, DFDV is following a familiar blueprint: accumulate, stake, and wait for the ecosystem to appreciate. The company has aligned itself closely with the Solana developer community and is reportedly exploring participation in validator nodes, staking pools, and liquidity provision—integrating deeper into the Solana DeFi stack. While its proposed $1 billion shelf offering has been paused, the ambition signals long-term conviction. By focusing on Solana—a chain known for speed, composability, and capital efficiency—DeFi Development is positioning itself as a yield-generating treasury operator with upside to network expansion. For investors, it’s one of the only ways to gain institutional-grade SOL exposure through an equity listing. Why Crypto Treasuries Matter in 2025 The rapid adoption of crypto treasury strategies reflects deeper shifts in how companies view capital. In a world of rising inflation, fiat dilution, and evolving investor preferences, holding cash—or even gold—is no longer enough. Digital assets offer not only appreciation potential but also yield, strategic alignment with Web3 ecosystems, and investor interest. Still, risks remain. Crypto markets are volatile, regulatory clarity varies, and altcoin-specific exposures can be speculative. But for companies willing to take the risk, the rewards have been substantial. For investors, these stocks offer a rare blend of public equity liquidity and crypto upside—without needing to manage wallets, private keys, or gas fees. As the crypto treasury model matures, expect more companies to follow suit—and more headlines to follow them. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Spetz Inc. assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 23, 2025 06:00 AM Eastern Daylight Time

Circle IPO Outperforms – Is a Meme Fork of Pepe Coin, APORK, the Next Institutional Surprise?

Angry Pepe Fork

Crypto infrastructure is no longer a fringe bet, as demonstrated by Circle's long-awaited IPO. Circle began trading on the NYSE at above $12 and closed 38% above the listing price, all on its opening day. Layer-1 networks and stablecoin startups continue to capture capital while a brand new type of asset is taking shape in a notable way. Out of nowhere, a new meme coin is popping up in market conversations. Angry Pepe Fork ( APORK ) with its unique branding is building a multi-chain, gamified, and community-driven universe. Let's explore and see how $APORK is quietly ticking the boxes for many institutions across the industry. Circle's Strong Start Changes the Playing Field Today, Circle, the cryptocurrency company behind the stablecoin USDC, ended its journey as a public company after going public, up 33.8% (due to the U.S. Senate’s landmark bill passing) and ahead of other fintech companies and almost all analysts. June 7th EOD prices marked $82.84, a 167% gain, afterwards, neutralizing to $107.70. The IPO's success has already caused hedge funds and Venture Capitalists to rethink their views of the entire crypto industry—what parts of the crypto market may be next for serious investment? $APORK, currently in presale, is one emerging token turning viral activity into serious amounts raised. Meme Coin, or Microeconomy? At first glance, Angry Pepe Fork $APORK may be seen as another meme project, but it is much more than that. It is designed with a CommunityFi & GambleFi economy, so users can earn not only by making purchases at the early stages of the project but by also participating in project long term and earning in the platform upon launch. Could Major Institutions Buy $APORK? While pension funds and ETFs are unlikely to directly hold meme tokens in the near future, smaller institutional investors like as crypto-native venture capitalists, investment firms, and crossover firms are looking for early-stage tokens with strong engagement metrics and scalable utility. $APORK's presale, includes staking returns of over 10,000% APY, a tiered incentive structure, and integrated gamified tokenomics which has already attracted thousands of people to its community and raised hundreds of thousands to its project. Cultural Capital + On-Chain Incentives The cryptocurrency world tends to be split on whether we refer to the narrative or infrastructure first. Bitcoin is digital gold; Ethereum is programmable finance; and meme currencies are representative of culture. $APORK is bridging cultural tokens to economic utility. While we don't know if $APORK is the next institutional surprise, its rise suggests that the meme currency space is no longer a joke. This could become the next serious play. Website: https://angrypepefork.com Angry Pepe Fork is the meme coin determined to push boundaries. Focused on going viral and offering real utility and multiple earning opportunities through CommunityFi missions, GambleFi gaming, and upcoming multi-chain bridging - all powered by a passionate, community-driven ethos. This is not financial advice. Do your own research before buying any cryptocurrency. While meme coins are powerful they are also subject to volatile fluctuations in value.WHILE THE VALUE OF $APORK CAN FLUCTUATE YOUR CONTRIBUTIONS WILL ALWAYS BE REWARDED. Contact Details Angry Pepe Fork APORK press@angrypepefork.com Company Website https://angrypepefork.com/

June 23, 2025 06:00 AM Eastern Daylight Time

Image

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)

Global Markets News

In a market where noise often overshadows substance, Nuvectis Pharma (NASDAQ:NVCT)* is delivering a signal that’s hard to ignore — sustained insider buying by one of the company’s most informed and sophisticated investors. On June 20, 2025, Charles Mosseri-Marlio, a well-known biotech investor and former pharmaceutical executive, filed a Form 4 disclosing the purchase of 33,442 additional shares of NVCT at $8.05 per share. The $270,000 transaction adds to his already significant position, which now totals just under 3 million shares through Emerald Hill Capital. This marks the third major insider buy by Mosseri-Marlio in 2025 alone — with previous purchases in February and May at lower price points. The pattern is clear: this is not opportunistic trading, it’s strategic accumulation. What makes this even more notable is Mosseri-Marlio’s background. He previously held a leadership role at Flamel Technologies (now Avadel Pharmaceuticals), where he helped secure development deals with top-tier partners like Pfizer and GlaxoSmithKline. He’s not only familiar with drug pipelines — he’s built them. Combined with a track record in institutional asset management, his buying carries more weight than your average insider move. He’s not chasing momentum — he’s betting on execution. And there’s plenty in the Nuvectis pipeline to justify that bet. The company is currently advancing two first-in-class oncology candidates — NXP800 and NXP900 — both of which are in clinical trials targeting cancers with high unmet need. NXP800 is in Phase 1b development for ARID1a-mutated, platinum-resistant ovarian cancer — a devastating subtype with few effective treatments. The drug has already earned Fast Track and Orphan Drug designations from the FDA, streamlining its development and signaling strong regulatory support. Data from this trial is expected later this year, and could be a key near-term catalyst. NXP900, meanwhile, is designed to address drug resistance in advanced cancers, including non-small cell lung cancer. By inhibiting SRC and YES1 kinases, NXP900 targets the very mechanisms that allow tumors to escape the effects of EGFR and ALK inhibitors — two of the most common first-line treatments in NSCLC. After completing its Phase 1a study, the company is now preparing to launch combination trials that could demonstrate its potential to restore drug sensitivity in resistant tumors. Despite these promising programs, Nuvectis remains deeply undervalued relative to peers. The company’s market cap sits around $150 million — a fraction of other precision oncology players at similar stages. Nuvalent (NASDAQ: NUVL), for example, trades north of $6 billion with programs focused on the same indication space. Summit Therapeutics (NASDAQ: SMMT), which also targets drug-resistant cancers, surged to nearly $15 billion in valuation earlier this year following a pivotal trial result. Nuvectis isn’t there yet — but if it delivers on either of its two clinical programs, it may not be far behind. Importantly, the company is financially stable. Nuvectis raised $15.5 million in early 2025, bringing its total cash reserves to nearly $30 million as of March. That provides runway into 2027, giving it ample time to reach key milestones without returning to the market for funding. It also means less dilution risk — a crucial factor for investors in early-stage biotech. This backdrop of strong insider ownership, solid financials, and high-impact drug development is what makes the Mosseri-Marlio buying spree so compelling. He’s not the only one with conviction either — CEO Ron Bentsur and other insiders continue to hold sizable stakes and have not sold a single share. Bentsur, notably, has a track record of taking biotech companies through FDA approval and delivering real value to shareholders. Year-to-date, NVCT is up significantly but it’s still relatively under the radar. That may not last long. With clinical data expected soon, strong internal alignment, and one of the most experienced insider buyers in the sector continuing to build his position, Nuvectis Pharma may be one of the few small-cap biotechs positioned for a breakout in the second half of 2025. - News Highlights from Nuvectis Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting - * Paid Advertisement Disclaimer & Disclosure: This content is not financial or investment advice, and the authors are not licensed brokers, dealers or advisors. This article was Published by the. Wall Street Wire™ platform and network, which is operated by Arx Advisory Ltd (the “Operators”). The Operators receive a monthly cash subscription fee from Nuvectis Pharma (NVCT) via bank transfer for services relating to promotional content and news distributions on various media and social channels. The Operators may received additional cash fees for monitoring, data or IR/advisory services on top of that. For specific details and full disclosures on the exact cash amounts paid for the Wall Street Wire subscription and the start date of such services, please refer to our full disclosure document: https://redditwire.com/terms Contact Details News Coverage media.globalmarkets@gmail.com

June 20, 2025 11:56 AM Eastern Daylight Time

1 2 3 4 5 ... 3892